Stockscreener 앱 받기
3.52
2.76%
-0.10
시장 영업 전:
3.74
0.22
+6.25%
전일 마감가:
$3.62
열려 있는:
$3.66
하루 거래량:
55,574
Relative Volume:
0.70
시가총액:
$35.36M
수익:
$1.15M
순이익/손실:
$-46.90M
주가수익비율:
-0.7014
EPS:
-5.0182
순현금흐름:
$-42.37M
1주 성능:
-12.00%
1개월 성능:
-29.60%
6개월 성능:
-61.49%
1년 성능:
-81.38%
1일 변동 폭
$3.50
$3.695
1주일 범위
$3.50
$4.3299
52주 변동 폭
$3.50
$29.98
Seres Therapeutics Inc Stock (MCRB) Company Profile
명칭
Seres Therapeutics Inc
전화
617 945 9626
주소
200 SIDNEY STREET, CAMBRIDGE, MA
Compare MCRB vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
3.52 | 35.36M | 1.15M | -46.90M | -42.37M | -5.0182 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-08 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2024-10-24 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-04-21 | 개시 | JP Morgan | Neutral |
| 2021-07-23 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-03-05 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2020-09-18 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2020-08-18 | 개시 | Piper Sandler | Overweight |
| 2020-08-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-11 | 업그레이드 | Jefferies | Hold → Buy |
| 2019-04-30 | 개시 | Jefferies | Hold |
| 2018-10-22 | 개시 | Chardan Capital Markets | Buy |
| 2017-10-13 | 개시 | Oppenheimer | Outperform |
| 2017-08-04 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-01 | 재확인 | FBR & Co. | Outperform |
| 2016-08-12 | 재확인 | FBR Capital | Outperform |
| 2016-08-01 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2016-08-01 | 재확인 | H.C. Wainwright | Buy |
| 2016-07-29 | 재개 | H.C. Wainwright | Buy |
| 2016-03-30 | 개시 | FBR Capital | Outperform |
| 2016-03-03 | 개시 | Guggenheim | Buy |
| 2016-01-25 | 개시 | H.C. Wainwright | Buy |
| 2015-10-22 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2015-07-22 | 개시 | Canaccord Genuity | Buy |
| 2015-07-21 | 개시 | Goldman | Neutral |
| 2015-07-21 | 개시 | Leerink Partners | Outperform |
모두보기
Seres Therapeutics Inc 주식(MCRB)의 최신 뉴스
Seres Therapeutics, Inc.(NasdaqGS: MCRB) dropped from S&P Global BMI Index - marketscreener.com
Seres Therapeutics stock holds steady as investors await next catalysts - AD HOC NEWS
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Two new hires get options on 4,200 Seres shares - Stock Titan
Microbiome Therapeutics Market Report 2026-2035 Featuring Profiles of Ferring Pharmaceuticals, Infant Bacterial Therapeutics, MaaT Pharma, Mikrobiomik, Seres Therapeutics, Vedanta Biosciences - Yahoo Finance
Microbiome Therapeutics Market Size, Share | Forecast [2034] - Fortune Business Insights
Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference - Stock Titan
Seres Therapeutics Inc. (MCRB) Peer Comparison – Compare with Others - Value Research
Seres Therapeutics Inc. (MCRB) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Seres Therapeutics (MCRB) Advances 3.23% to $5.11 as Biotech Stock Holds Key Support ZoneCall Wall - siam.in
Seres (MCRB) Earnings Report: The Available Earnings Metric Delivers a Beat; Post-Report: The Stock Ends Up 2.19%Profit Growth Outlook - vinanet.vn
MCRB|Seres Therapeutics Inc|Price:4.660|Chg%:+0.100 - TradingKey
MCRB Should I Buy - Intellectia AI
Seres Therapeutics reports positive SER-155 irEC study results - scanx.trade
Seres Therapeutics director Eric Shaff sells $1,196 in shares By Investing.com - Investing.com South Africa
Seres Therapeutics director Eric Shaff sells $1,196 in shares - Investing.com
Seres Therapeutics (NASDAQ: MCRB) COO sells 64 shares after 181 RSUs vest - Stock Titan
Seres Therapeutics (MCRB) director sale tied to RSU tax plan - Stock Titan
Seres Therapeutics, Inc. Revenue Breakdown – NASDAQ:MCRB - TradingView
Seres TherapeuticsMay Offer Up To $300 Million Of Securities - TradingView
Seres Therapeutics Files $300 Million Mixed Shelf - Yahoo Finance
MCRB Stock Declines As Seres Therapeutics Pauses SER-155 Phase 2 Study And Shrinks Headcount By 30% - Stocktwits
Seres Therapeutics Inc (MCRB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CCORF Maintains Seres Therapeutics(MCRB.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Seres Therapeutics exits more Cambridge real estate early - The Business Journals
Seres Therapeutics Inc earnings beat by $2.77, revenue topped estimates - Investing.com
Seres Therapeutics Q2 Operating Income USD -2 - Moomoo
Seres Therapeutics, Inc. 2Q 2026: Revenue $0.736M, Net income $4.581M, EPS $0.47— 10-Q Summary - TradingView
Seres Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Seres Therapeutics (MCRB) Q2 Revenue Surpasses Expectations Amid Clinical Progress - GuruFocus
Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs - The Manila Times
Seres Therapeutics Q2 Net Income Reaches $4.6 Million - Quiver Quantitative
Seres Therapeutics: Q2 Earnings Snapshot - marketscreener.com
Seres Therapeutics reports Q2 2026 net income of $4.6M, cash $15.6M, advances SER-155 clinical plans - TradingView
MCRB: Returned to profitability in Q2 2026, driven by VOWST sale gains and SER-155 trial success - TradingView
Q2 2026 financial results released as Seres Therapeutics advances business update - Traders Union
Seres Therapeutics Reports Second Quarter 2026 Financial - GlobeNewswire
Seres Therapeutics (MCRB) Unchanged at $5.25 as Consolidation Tightens Between Support and ResistanceInitial Balance - dars.gov.et
Seres Therapeutics Streamlines Cambridge Operations with Lease Changes - TipRanks
MCRB Q2'26 Earnings: EPS estimate is (2.19) USD - TradingView
Seres Therapeutics Inc expected to post a loss of $2.18 a shareEarnings Preview - TradingView
MCRB Q2'26 Earnings: revenue estimate is 179.00K USD - TradingView
Seres Therapeutics Inc (MCRB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Seres Therapeutics Inc (MCRB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Seres Therapeutics (MCRB) Dips 2.32% as Shares Test Support LevelGamma Flip Level - vinanet.vn
TradingKey - TradingKey
Seres Therapeutics Inc (MCRB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Seres Therapeutics Inc Revenue Breakdown – BX:MCRB - TradingView
Seres Therapeutics Inc (MCRB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
MCRB|Seres Therapeutics Inc|Price:4.980|Chg%:-0.250 - TradingKey
Seres Therapeutics Inc (MCRB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Seres Therapeutics Inc (MCRB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):